Nbe-Therapeutics Ag company information, Employees & Contact Information

NBE Therapeutics opens new ADC research facility in Switzerland Pharmaceutical Technology

Boehringer commits $31M to ADC R&D via new Swiss facility for NBE Therapeutics Fierce Biotech

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel GlobeNewswire

Low-key interest in ROR1 continues | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Boehringer Ingelheim Opens New R&D Center in Basel CHEManager

NBE Therapeutics opens new location in Basel Switzerland Global Enterprise

Boehringer Ingelheim opens new ADC facility in Basel, Switzerland World Pharmaceutical Frontiers

Destroying cancer cells and providing antitumor immunity Nature

Sotio reveals its ADC hand | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Boehringer to Acquire NBE-Therapeutics in €1.2B Transaction Contract Pharma

Boehringer goes after antibody cancer drugs in latest acquisition BioPharma Dive

Boehringer spends €1.18bn to acquire NBE-Therapeutics PMLiVE

Boehringer to acquire NBE-Therapeutics for enhancing cancer pipeline Pharmaceutical Technology

Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race Fierce Biotech

Acquisition Agreement with Boehringer Ingelheim for NBE-Therapeutics Marks First Major Biotech Exit for PPF Group GlobeNewswire

Boehringer’s latest conjugate deal rings some old bells | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Sotio builds a presence in antibody conjugates | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Ipsen buys into ROR1 after Boehringer’s exit | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

No giving up on ROR1 for Oncternal | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

NBE Therapeutics entices Boehringer for $22m series C - Global Venturing

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology Labiotech.eu

Lonza's Synaffix adds Boehringer to its constellation of partners with $1.3B ADC tech pact Fierce Biotech

Exelixis: Deals with NBE and Catalent bring multi-pronged ADC approach BioProcess International

Boehringer invests $30 million into antibody drug conjugate research and development BioProcess International

Boehringer takes on AbbVie in a novel checkpoint | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

NBE Therapeutics begins clinical trial of antibody-drug conjugate The Science Advisory Board

NBE closes $22 million Series C for cancer drug trials The Pharma Letter

Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology Yahoo Finance

Pheon nabs $68M to ready clinical launch based on ADC-featured pipeline Fierce Biotech

Boehringer gains access to Synaffix’s ADC technology through $1.3bn licensing deal PMLiVE

Sotio taps Biocytogen to create bispecific ADCs in $326M deal Fierce Biotech

Boehringer Ingelheim acquires T3 Pharma Switzerland Global Enterprise

Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio The Manila Times

Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight GlobeNewswire

Novartis to Buy Cadent Therapeutics for Up to $770 Million Bloomberg

SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology PharmiWeb.com

Genedata acquired by Danaher Switzerland Global Enterprise

Cheplapharm has major plans for the Basel Area Switzerland Global Enterprise

Clear Solutions Labs seeks to benefit from the Basel Area Switzerland Global Enterprise

SixPeaks Bio debuts with financing of 110 million US dollars Switzerland Global Enterprise

New BIIE research institute established in Basel Switzerland Global Enterprise

Roche named as the most future-ready pharma company Switzerland Global Enterprise

CSL joins Basel biotech cluster Switzerland Global Enterprise

CordenPharma set to invest more than 500 million euros in Muttenz Switzerland Global Enterprise

Switzerland attracts more foreign investments Switzerland Global Enterprise

Chemspeed acquired by Bruker Switzerland Global Enterprise

Four new buildings planned for Switzerland Innovation Park Basel Area Switzerland Global Enterprise

Switzerland is one of the happiest countries in the world Switzerland Global Enterprise